Menstrual cup use, leakage, acceptability, safety, and availability: a systematic review and meta-analysis.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
08 2019
Historique:
received: 28 02 2019
revised: 15 06 2019
accepted: 17 06 2019
pubmed: 22 7 2019
medline: 19 6 2020
entrez: 21 7 2019
Statut: ppublish

Résumé

Girls and women need effective, safe, and affordable menstrual products. Single-use products are regularly selected by agencies for resource-poor settings; the menstrual cup is a less known alternative. We reviewed international studies on menstrual cup leakage, acceptability, and safety and explored menstrual cup availability to inform programmes. In this systematic review and meta-analysis, we searched PubMed, Cochrane Library, Web of Science, Popline, Cinahl, Global Health database, Emerald, Google Scholar, Science.gov, and WorldWideScience from database inception to May 14, 2019, for quantitative or qualitative studies published in English on experiences and leakage associated with menstrual cups, and adverse event reports. We also screened the Manufacturer and User Facility Device Experience database from the US Food and Drug Administration for events related to menstrual cups. To be eligible for inclusion, the material needed to have information on leakage, acceptability, or safety of menstrual cups. The main outcome of interest was menstrual blood leakage when using a menstrual cup. Safety outcomes of interest included serious adverse events; vaginal abrasions and effects on vaginal microflora; effects on the reproductive, digestive, or urinary tract; and safety in poor sanitary conditions. Findings were tabulated or combined by use of forest plots (random-effects meta-analysis). We also did preliminary estimates on costs and environmental savings potentially associated with cups. This systematic review is registered on PROSPERO, number CRD42016047845. Of 436 records identified, 43 studies were eligible for analysis (3319 participants). Most studies reported on vaginal cups (27 [63%] vaginal cups, five [12%] cervical cups, and 11 [25%] mixed types of cups or unknown) and 15 were from low-income and middle-income countries. 22 studies were included in qualitative or quantitative syntheses, of which only three were of moderate-to-high quality. Four studies made a direct comparison between menstrual cups and usual products for the main outcome of leakage and reported leakage was similar or lower for menstrual cups than for disposable pads or tampons (n=293). In all qualitative studies, the adoption of the menstrual cup required a familiarisation phase over several menstrual cycles and peer support improved uptake (two studies in developing countries). In 13 studies, 73% (pooled estimate: n=1144; 95% CI 59-84, I Our review indicates that menstrual cups are a safe option for menstruation management and are being used internationally. Good quality studies in this field are needed. Further studies are needed on cost-effectiveness and environmental effect comparing different menstrual products. UK Medical Research Council, Department for International Development, and Wellcome Trust.

Sections du résumé

BACKGROUND
Girls and women need effective, safe, and affordable menstrual products. Single-use products are regularly selected by agencies for resource-poor settings; the menstrual cup is a less known alternative. We reviewed international studies on menstrual cup leakage, acceptability, and safety and explored menstrual cup availability to inform programmes.
METHODS
In this systematic review and meta-analysis, we searched PubMed, Cochrane Library, Web of Science, Popline, Cinahl, Global Health database, Emerald, Google Scholar, Science.gov, and WorldWideScience from database inception to May 14, 2019, for quantitative or qualitative studies published in English on experiences and leakage associated with menstrual cups, and adverse event reports. We also screened the Manufacturer and User Facility Device Experience database from the US Food and Drug Administration for events related to menstrual cups. To be eligible for inclusion, the material needed to have information on leakage, acceptability, or safety of menstrual cups. The main outcome of interest was menstrual blood leakage when using a menstrual cup. Safety outcomes of interest included serious adverse events; vaginal abrasions and effects on vaginal microflora; effects on the reproductive, digestive, or urinary tract; and safety in poor sanitary conditions. Findings were tabulated or combined by use of forest plots (random-effects meta-analysis). We also did preliminary estimates on costs and environmental savings potentially associated with cups. This systematic review is registered on PROSPERO, number CRD42016047845.
FINDINGS
Of 436 records identified, 43 studies were eligible for analysis (3319 participants). Most studies reported on vaginal cups (27 [63%] vaginal cups, five [12%] cervical cups, and 11 [25%] mixed types of cups or unknown) and 15 were from low-income and middle-income countries. 22 studies were included in qualitative or quantitative syntheses, of which only three were of moderate-to-high quality. Four studies made a direct comparison between menstrual cups and usual products for the main outcome of leakage and reported leakage was similar or lower for menstrual cups than for disposable pads or tampons (n=293). In all qualitative studies, the adoption of the menstrual cup required a familiarisation phase over several menstrual cycles and peer support improved uptake (two studies in developing countries). In 13 studies, 73% (pooled estimate: n=1144; 95% CI 59-84, I
INTERPRETATION
Our review indicates that menstrual cups are a safe option for menstruation management and are being used internationally. Good quality studies in this field are needed. Further studies are needed on cost-effectiveness and environmental effect comparing different menstrual products.
FUNDING
UK Medical Research Council, Department for International Development, and Wellcome Trust.

Identifiants

pubmed: 31324419
pii: S2468-2667(19)30111-2
doi: 10.1016/S2468-2667(19)30111-2
pmc: PMC6669309
pii:
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e376-e393

Subventions

Organisme : Medical Research Council
ID : G1100677
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N006046/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Contraception. 2009 Jun;79(6):463-8
pubmed: 19442783
Female Pelvic Med Reconstr Surg. 2016 Sep-Oct;22(5):e29-31
pubmed: 27403759
PLoS Med. 2016 Feb 23;13(2):e1001962
pubmed: 26908274
BMJ Open. 2016 Mar 02;6(3):e010290
pubmed: 26936906
Obstet Gynecol. 1962 May;19:688-91
pubmed: 14454013
Contraception. 1991 Dec;44(6):607-21
pubmed: 1773618
Health Care Women Int. 2014;35(6):677-94
pubmed: 24527840
Infect Dis Obstet Gynecol. 1994;2(3):140-5
pubmed: 18475381
Rev Infect Dis. 1989 Jan-Feb;11 Suppl 1:S43-8; discussion S48-9
pubmed: 2928652
Appl Environ Microbiol. 2018 May 31;84(12):
pubmed: 29678918
J Womens Health (Larchmt). 2015 Feb;24(2):151-8
pubmed: 25682816
Contraception. 2012 Aug;86(2):119-21
pubmed: 22464406
Can Fam Physician. 2011 Jun;57(6):e208-15
pubmed: 21673197
J Womens Health (Larchmt). 2015 Oct;24(10):801-11
pubmed: 26296186
Med J Aust. 1990 Jan 1;152(1):52-3
pubmed: 2403627
J Obstet Gynaecol. 2010 Apr;30(3):285-7
pubmed: 20373933
Aust N Z J Obstet Gynaecol. 1993 Feb;33(1):79-80
pubmed: 8498947
J Fam Plann Reprod Health Care. 2017 Apr;43(2):157-159
pubmed: 27507295
BMJ Open. 2016 Nov 23;6(11):e013229
pubmed: 27881530
Int J Equity Health. 2016 Jun 06;15:86
pubmed: 27268416
Gynecol Obstet Invest. 2003;56(1):35-7
pubmed: 12867766
PLoS One. 2015 Jun 30;10(6):e0130777
pubmed: 26125184
Rev Infect Dis. 1989 Jan-Feb;11 Suppl 1:S182-6; discussion S186-7
pubmed: 2928635
Obstet Gynecol. 2002 Oct;100(4):683-7
pubmed: 12383534
Aust N Z J Obstet Gynaecol. 1989 Aug;29(3 Pt 1):275
pubmed: 2604667
PLoS One. 2016 Dec 21;11(12):e0166122
pubmed: 28002415
Can J Infect Dis Med Microbiol. 2015 Jul-Aug;26(4):218-20
pubmed: 26361491
J Adolesc. 2010 Aug;33(4):521-9
pubmed: 19395018
Obstet Gynecol. 1962 May;19:684-7
pubmed: 14485045
Int J Fertil. 1964 Oct-Dec;9:619-21
pubmed: 14215360
BMC Infect Dis. 2018 Sep 21;18(1):473
pubmed: 30241498
Reprod Health. 2018 Aug 17;15(1):139
pubmed: 30119636
Contraception. 2019 Jul;100(1):85-87
pubmed: 30981842
BMJ Open. 2017 May 4;7(4):e015429
pubmed: 28473520
BMJ Open. 2016 Dec 30;6(12):e012596
pubmed: 28039290
Fertil Steril. 1995 Sep;64(3):661-3
pubmed: 7641929
J Obstet Gynaecol. 2009 Jan;29(1):49-52
pubmed: 19280496
Obstet Gynecol. 2019 Feb;133(2):238-244
pubmed: 30633137
Case Rep Womens Health. 2019 Mar 16;22:e00108
pubmed: 30949437
Int J STD AIDS. 2012 May;23(5):367-8
pubmed: 22648895
PLoS One. 2012;7(10):e48274
pubmed: 23118968
Obstet Gynecol. 2016 Dec;128(6):1365-1368
pubmed: 27824744
PLoS One. 2013 Nov 14;8(11):e79132
pubmed: 24244435
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
PLoS One. 2018 Nov 28;13(11):e0207925
pubmed: 30485344
Int J Surg Case Rep. 2018;46:28-30
pubmed: 29665512
J Womens Health (Larchmt). 2011 Feb;20(2):303-11
pubmed: 21194348
Emerg Infect Dis. 1999 Nov-Dec;5(6):807-10
pubmed: 10603216
S Afr Med J. 2015 Apr 08;105(5):331
pubmed: 26242650

Auteurs

Anna Maria van Eijk (AM)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Garazi Zulaika (G)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Madeline Lenchner (M)

Population Health Sciences, Institute of Epidemiology and Health Care, University College London, London, UK.

Linda Mason (L)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.

Muthusamy Sivakami (M)

Centre for Health and Social Sciences, School of Health Systems Studies, Tata Institute of Social Sciences, Mumbai, Maharashtra, India.

Elizabeth Nyothach (E)

Centre for Global Health Research, Kenya Medical Research Institute (KEMRI), Kisumu, Kenya.

Holger Unger (H)

Centre for Maternal and Newborn Health, Liverpool School of Tropical Medicine, Liverpool, UK; Department of Obstetrics and Gynaecology, Edinburgh Royal Infirmary, Edinburgh, UK.

Kayla Laserson (K)

Bill & Melinda Gates Foundation, India Country Office, New Delhi, India.

Penelope A Phillips-Howard (PA)

Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK. Electronic address: penelope.phillips-howard@lstmed.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH